Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer.
The purpose of this study was to compare chemotherapy-naive patients with stage IV nonsmall cell lung cancer patients treated with chemotherapy or chemoimmunotherapy. We tested doxetacel plus cisplatinum as chemotherapy protocol. An immunomodulatory adjuvant system was added as chemoimmunotherapy to the previously mentioned protocol. This system contains three well-known and complementary conditioners of protective immune-responses: cyclophosphamide low-dose, granulocyte macrophage-colony stimulant factor and magnesium silicate granuloma. Eighty-eight patients were randomly assigned to receive every 3-weeks one of the treatments under comparison. Patients received four cycles of treatment unless disease progression or unacceptable toxicity was documented. The maximum follow-up was one year. In each arm, tumor response (rate,duration), median survival time, 1-year overall survival, safety, and immunity modifications were assessed. Immunity was evaluated by submitting peripheral blood mononuclear cells to laboratory tests for nonspecific immunity: a) phytohemaglutinin-induced lymphocyte proliferation, b) prevalence of T-Regulatory (CD4+CD25+) cells and for specific immunity: a) lymphocyte proliferation induced by tumor-associated antigens (TAA) contained in a previously described autologous thermostable hemoderivative. The difference (chemotherapy vs. chemoimmunotherapy) in response rate induced by the two treatments (39.0% and 35.0%) was not statistically significant. However, the response duration (22 and 31 weeks), the median survival time (32 and 44 weeks) and 1-year survival (33.3% and 39.1%) were statistically higher with chemoimmunotherapy. No difference in toxicity between both arms was demonstrated. A switch in the laboratory immunity profile, nonspecific and specific, was associated with the chemoimmunotherapy treatment: increase of proliferative lymphocyte response, decrease of tolerogenic T-regulatory cells and eliciting TAA-sensitization.
Lasalvia-Prisco
Eduardo
E
Interdoctors Medical Procedures, North Miami Beach, FL, USA;
Garcia-Giralt
Emilio
E
Vázquez
Jesús
J
Aghazarian
Marta
M
Lasalvia-Galante
Eduardo
E
Larrañaga
Joshemaria
J
Spera
Gonzalo
G
Chest. 2003 Jan;123(1 Suppl):226S-243S
12527582
Am J Clin Oncol. 1982 Dec;5(6):649-55
7165009
Med Oncol. 2006;23(1):91-104
16645234
Clin Med Res. 2005 Nov;3(4):221-8
16303887
Immunol Rev. 2002 Oct;188:147-54
12445288
Ann Immunol (Paris). 1977 Jul-Oct;128C(4-5):923-8
900902
Oncologist. 2000;5(6):497-500
11110601
Blood. 2002 Dec 1;100(12):4108-15
12393401
J Urol. 2006 Jun;175(6):2087-91
16697809
Ann Intern Med. 2001 Apr 17;134(8):663-94
11304107
Proc Natl Acad Sci U S A. 1983 Oct;80(20):6395-8
6578514
Eur J Immunol. 2004 Feb;34(2):336-44
14768038
Ann N Y Acad Sci. 1979;332:135-47
316979
Cancer Biol Ther. 2003 Mar-Apr;2(2):155-60
12750554
Blood. 1996 Jul 1;88(1):202-10
8704175
Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S115-24
17259552
J Mol Med (Berl). 1999 Dec;77(12):824-33
10682318
Lancet. 2001 Apr 14;357(9263):1191-4
11323066
Immunol Lett. 1987 Dec;16(3-4):199-203
3443469
Proc Natl Acad Sci U S A. 1992 May 15;89(10):4358-62
1584770
J Clin Oncol. 2004 Jul 1;22(13):2602-9
15226327
Nat Med. 1998 May;4(5):581-7
9585232
Clin Trials. 2006;3(4):335-48
17060208
Neoplasma. 1982;29(1):93-110
6280082
Breast Cancer Res Treat. 2006 Nov;100(2):149-60
16819567
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Biologics. 2007 Jun;1(2):173-81
19707327
N Engl J Med. 2004 May 20;350(21):2129-39
15118073
Cancer Treat Rep. 1978 Jul;62(7):1059-63
356968
Cancer Res. 1982 Nov;42(11):4862-6
7127320
Nat Rev Immunol. 2006 Sep;6(9):659-70
16932751